Business Context and Reporting Period
Company: Incyte Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1999
Business Overview: Incyte is a provider of genomic information-based products and services, including database products, bioinformatics software, microarray-based gene expression services, and genomic reagents. The company serves pharmaceutical and biotechnology companies and academic researchers to assist in drug discovery and development. As of December 31, 1999, Incyte held agreements with over 20 major pharmaceutical and biotechnology companies for non-exclusive database access.
Key Financial Metrics
| Metric (in thousands, except per share) | 1999 | 1998 | 1997 |
|---|---|---|---|
| Revenues | $156,962 | $134,811 | $89,996 |
| Net Income (Loss) | $(26,768) | $3,472 | $6,908 |
| Basic EPS | $(0.95) | $0.13 | $0.28 |
| Diluted EPS | $(0.95) | $0.12 | $0.26 |
| Research & Development Expenses | $146,833 | $97,192 | $72,452 |
| Selling, General & Admin Expenses | $37,235 | $25,438 | $13,928 |
| Cash, Cash Equivalents & Marketable Securities | $66,937 | $111,233 | $113,095 |
| Working Capital | $58,043 | $81,437 | $90,700 |
| Accumulated Deficit | $(55,169) | $(28,401) | $(30,129) |
Debt & Liquidity: As of December 31, 1999, the company had minimal long-term debt ($194,000 non-current portion of capital leases/notes). However, in February 2000 (subsequent to year-end), Incyte issued $200 million in convertible subordinated notes and raised an additional $398.3 million through a private placement of common stock.
Material Changes vs. Prior Period
- Profitability Reversal: The company shifted from a net income of $3.5 million in 1998 to a net loss of $26.8 million in 1999. This was primarily driven by a significant increase in Research and Development (R&D) expenses.
- R&D Spending Surge: R&D expenses increased by approximately 51% year-over-year (from $97.2 million to $146.8 million). This increase was attributed to new genomic sequencing, genetic mapping, and Single Nucleotide Polymorphism (SNP) discovery initiatives launched in late 1998, as well as a collaboration with Oxford GlycoSciences.
- Revenue Growth: Revenues grew 16% to $157.0 million, driven by expanded database agreements and increased microarray-related services. Over 83% of 1999 revenues were derived from database collaborations.
- Cash Position: Cash and marketable securities decreased by approximately $44.3 million (from $111.2 million to $66.9 million) due to operating losses and capital expenditures of $34.8 million.
- Joint Venture Losses: Losses from the diaDexus joint venture increased to $5.6 million in 1999 from $1.5 million in 1998.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects to report a net loss for the year ending December 31, 2000, due to continued heavy investment in sequencing, bioinformatics, expression database development, and SNP discovery programs.
- Capital Resources: Based on current plans and the February 2000 financing, management believes existing resources are adequate for at least the next twelve months.
- Legal Contingencies (Affymetrix Litigation): Incyte is involved in patent infringement lawsuits filed by Affymetrix, Inc. in 1998 regarding microarray technology. Affymetrix seeks permanent injunctions and treble damages. The company cannot estimate the potential loss but notes the litigation has resulted in substantial expenses (approx. $6.5 million in 1999 legal fees) and diversion of management effort.
- Key Risks:
- Patent Uncertainty: The scope of patent protection for gene sequences and SNPs is uncertain. Competitors may establish patent positions or make sequences publicly available, reducing the value of Incyte's databases.
- Customer Concentration: While no single customer contributed more than 10% of revenue in 1999, the business relies heavily on retaining database collaborators. One collaborator did not renew its subscription in 1999.
- Technology Obsolescence: Rapid technological change in sequencing and microarray technology poses a risk to the company's competitive position.
Investor Verification Checklist
- Legal Exposure: Verify the current status and potential financial impact of the Affymetrix patent litigation, including any settlement discussions or court rulings post-filing.
- Revenue Sustainability: Confirm the renewal rates of the 20+ database collaboration agreements and the specific terms regarding milestone payments and royalties.
- Capital Adequacy: Review the terms of the $200 million convertible notes and the $398 million equity raise completed in February 2000 to assess dilution and debt service obligations.
- R&D Efficiency: Monitor the progress of SNP discovery and genomic sequencing programs to ensure they generate future revenue streams commensurate with the $147 million invested in 1999.
- Joint Venture Viability: Assess the financial health and funding requirements of the diaDexus joint venture, which reported significant losses in 1999.